Xiulei Mo

Xiulei Mo

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
CTCong Tang
Cong Tang
XMXiulei Mo
Xiulei Mo
QNQiankun Niu
Qiankun Niu
AWAlafate Wahafu
Alafate Wahafu
XYXuan Yang
Xuan Yang
HFHaian Fu
Haian Fu


15 November 2023 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
WOWukun Ouyang
Wukun Ouyang
QLQianjin Li
Qianjin Li
QNQiankun Niu
Qiankun Niu
MQMin Qui
Min Qui
HFHaian Fu
Haian Fu
XMXiulei Mo
Xiulei Mo
The transforming growth factor-beta (TGFβ) signaling pathway plays crucial roles in the establishment of an immunosuppressive tumor microenvironment, making anti-TGFβ agents a significant area of interest in cancer immunotherapy. However, the clinical translation of current anti-TGFβ agents that target upstream cytokines and receptors remains challenging. Therefore, the development of small-molecule inhibitors specifically targeting SMAD4, the downstream master regulator of the TGFβ pathway, would offer an alternative approach with significant therapeutic potential for anti-TGFβ signaling. In this study, we present the development of a cell lysate-based multiplexed time-resolved fluorescence resonance energy transfer (TR-FRET) assay in an ultrahigh-throughput screening (uHTS) 1536-well plate format. This assay enables simultaneous monitoring of the protein‒protein interaction between SMAD4 and SMAD3, as well as the protein‒DNA interaction between SMADs and their consensus DNA-binding motif. The multiplexed TR-FRET assay exhibits high sensitivity, allowing the dynamic analysis of the SMAD4–SMAD3–DNA complex at single-amino acid resolution. Moreover, the multiplexed uHTS assay demonstrates robustness for screening small-molecule inhibitors. Through a pilot screening of an FDA-approved bioactive compound library, we identified gambogic acid and gambogenic acid as potential hit compounds. These proof-of-concept findings underscore the utility of our optimized multiplexed TR-FRET platform for large-scale screening to discover small-molecule inhibitors that target the SMAD4–SMAD3–DNA complex as novel anti-TGFβ signaling agents.

8 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CSChangfa Shu
Changfa Shu
JLJianfeng Li
Jianfeng Li
JRJin Rui
Jin Rui
DFDacheng Fan
Dacheng Fan
QNQiankun Niu
Qiankun Niu
HFHaian Fu
Haian Fu
Harnessing the power of immune system to treat cancer has become a core clinical approach. However, rewiring of intrinsic circuitry by genomic alterations enables tumor cells to escape immune surveillance, leading to therapeutic failure. Uncovering the molecular basis of how tumor mutations induce therapeutic resistance may guide the development of intervention approaches to advance precision immunotherapy. Here we report the identification of the Liver Kinase B1 (LKB1)-Inhibitor of Apoptosis Protein (IAP)- Janus Kinase 1 (JAK1) dynamic complex as a molecular determinant for immune response of LKB1-mut lung cancer cells. LKB1 alteration exposes a critical dependency of lung cancer cells on IAP for their immune resistance. Indeed, pharmacological inhibition of IAP re-establishes JAK1-regulated Stimulator of interferon genes (STING) expression and DNA sensing signaling, enhances cytotoxic immune cell infiltration, and augmentes immune-dependent anti-tumor activity in an LKB1-mutant immune-competent mouse model. Thus, IAP-JAK1-targeted strategies, like IAP inhibitors, may offer a promising therapeutic approach to restore the responsiveness of immunologically-cold LKB1-mutant tumors to immune checkpoint inhibitors or STING-directed therapies.

8 September 2021 in STAR Protocols
Verified
Journal Article
Open access
CTCong Tang
Cong Tang
QNQiankun Niu
Qiankun Niu
DCDanielle Cicka
Danielle Cicka
YDYuhong Du
Yuhong Du
XMXiulei Mo
Xiulei Mo
HFHaian Fu
Haian Fu
Protein-protein interactions (PPIs) have emerged as promising yet challenging therapeutic targets. A robust bioassay is required for rapid PPI modulator discovery. Here, we present a time-resolved Förster's (fluorescence) resonance energy transfer assay protocol for PPI modulator screening in a 1536-well plate format. We use hypomorph SMAD4R361H-SMAD3 PPI as an example to illustrate the application of the protocol for screening of variant-directed PPI inducers. This platform can be readily adapted for the discovery of both small-molecule PPI inducers and inhibitors.

1 June 2025 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
WOWukun Ouyang
Wukun Ouyang
JHJiaying Hao
Jiaying Hao
QNQiankun Niu
Qiankun Niu
EDEugene F Douglass
Eugene F Douglass
CBChristian M Beusch
Christian M Beusch
XMXiulei Mo
Xiulei Mo
SMAD4, a central mediator of the TGF-β signaling pathway, plays a critical role in regulating cellular processes such as proliferation, differentiation, and apoptosis. While SMAD4’s canonical functions within TGF-β signaling are well-established, its non-canonical, TGF-β-independent roles remain poorly understood, particularly in the context of disease biology. Here, we investigate SMAD4’s TGF-β-independent functions by identifying and characterizing its protein–protein interaction network. Using pancreatic ductal adenocarcinoma as a model system, we performed a SMAD4-focused oncogenic protein–protein interaction mapping and uncovered a novel interaction between SMAD4 and NFATc1. We demonstrated that SMAD4 binds to NFATc1 in a phosphorylation-dependent but TGF-β-independent manner, sequestering NFATc1 in the cytoplasm and inhibiting its transcriptional activity. The absence of this interaction in SMAD4-deficient PDAC cells is associated with the activation of NFATc1 transcriptional programs and upregulation of STAT3 at both mRNA and protein levels. Pharmacological profiling revealed multiple STAT3 inhibitors with selective efficacy against SMAD4-deficient PDAC cells in vitro, highlighting a potential therapeutic vulnerability. These findings identify a previously uncharacterized SMAD4–NFATc1 regulatory complex and establish its biological significance in regulating NFATc1-driven transcriptional programs, such as STAT3, providing critical insights into SMAD4’s TGF-β-independent functions and uncovering new opportunities for therapeutic intervention in SMAD4-deficient contexts.